Cantor Fitzgerald Starts Lineage Cell Therapeutics Inc. (LCTX) at Overweight

March 30, 2021 4:03 PM EDT
Get Alerts LCTX Hot Sheet
Price: $2.41 -6.59%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 3 | Down: 2 | New: 21
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Lineage Cell Therapeutics Inc. (NYSE: LCTX) with a Overweight rating and a price target of $6.00.

The analyst comments "We are initiating coverage of Lineage Cell Therapeutics (LCTX) with an OW rating, and 12-month PT of $6. LCTX is an allogeneic cell therapy company evaluating the potential of OpRegen for dry AMD with geographic atrophy (GA), OPC1 for spinal cord injuries (SCIs), and VAC2 for cancer. The company has in-house manufacturing and know-how capabilities to develop specialized, terminally-differentiated human cells intended to either replace or support dysfunctional/absent cells. In our view, the company has demonstrated transformational benefits across the two lead programs, which we believe could each equate to >$1B in peak sales. Lineage has guided for many data and execution events over the next 12-months which we believe could drive further upside."

For an analyst ratings summary and ratings history on Lineage Cell Therapeutics Inc. click here. For more ratings news on Lineage Cell Therapeutics Inc. click here.

Shares of Lineage Cell Therapeutics Inc. closed at $2.14 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

Cantor Fitzgerald